Business
Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule VK2735 Phase 1 Maintenance
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"\n Conference call scheduled for 4:30 p.m. ET today\n \n \n \n Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Proceeding on Schedule\n \n \n VK2735 Phase 1 Maintenance Dosing Study Underway\n \n \n Additional Phase 2a VENTURE Study Data to be Presented at ObesityWeek in November\n \n \n Strong Quarter-End Cash Position of $715 Million\n \n \n \n SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2025, and provided an update on its clinical pipeline and other corporate developments.\n \n \n \n \n \n \n \n \n Highlights from the Quarter Ended September 30, 2025, and Other Recent Events:\n \n \"During the first three quarters of 2025, Viking made strong and steady progress with each of our active programs, with new data reported in the third quarter that further positions our lead obesity program as potentially best-in-class,\" stated Brian Lian, Ph.D., chief executive officer of Viking. \"In the third quarter, we announced positive top-line results from the Phase 2 VENTURE-Oral Dosing study of VK2735, which successfully achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight of up to 12.2% from baseline. The study also evaluated a maintenance dosing cohort which demonstrated that the rapid weight loss achieved from brief exposures at high doses was not only maintained but further extended following down-titration to a lower daily dose. The impressive oral efficacy and low-dose maintenance data highlight VK2735's differentiated profile, offering additional dosing options to complement weekly subcutaneous dosing. In the second quarter, Viking initiated the Phase 3 VANQUISH registration program, including trials in patients with obesity and obesity with type 2 diabetes. Enrollment in these trials is proceeding well. We expect to complete enrollment in the VANQUISH-1 study later this quarter, with VANQUISH-2 to follow in the first quarter of 2026. The rapid pace of enrollment in these trials reflects the enthusiasm we've received from both patients and clinical investigators. F...